Alkem Laboratories Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alkem Laboratories Ltd
Women’s health specialist Theramex has struck a deal with Alkem’s Enzene Biosciences biotech subsidiary to gain rights to Enzene’s proposed denosumab biosimilar version of Prolia in Europe and Australia.
India’s Alkem Laboratories has reported double-digit growth in its US business for financial year 2021, after seeing its US business double in four years. The company also saw recovery in its domestic business on the back of robust growth delivered by its generics business.
India’s Alkem has announced growing domestically in its financial third quarter, after seeing a low first quarter due to COVID-19. The company has also reported progress in the international market, after receiving 10 ANDA approvals from the US FDA in Q3 FY21.
With the approval in India of its Enzene subsidiary’s version of teriparatide, Alkem is setting its sights on the biosimilars market.